Calidi Biotherapeutics, Inc.
CLDI · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 0.03 | 0.02 | 0.01 |
| FCF Yield | -57.18% | -62.17% | -46.76% | -59.20% |
| EV / EBITDA | -0.04 | -1.26 | -2.05 | -1.85 |
| Quality | ||||
| ROIC | -45.43% | -91.50% | -41.87% | -44.09% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.82 | 0.85 | 1.41 | 1.31 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 13.61% | 30.83% | -31.50% | -9.61% |
| Safety | ||||
| Net Debt / EBITDA | 1.54 | 0.24 | 1.27 | 0.71 |
| Interest Coverage | -123.12 | -108.92 | -70.31 | -23.01 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -240.91 | 0.00 | 0.00 | -474.50 |